1/3
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/19
10:37 am
sndx
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors
Low
Report
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors
12/10
08:01 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
12/9
07:42 am
sndx
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial [Yahoo! Finance]
High
Report
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial [Yahoo! Finance]
12/9
07:30 am
sndx
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Medium
Report
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
12/7
06:18 pm
sndx
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting [Yahoo! Finance]
Medium
Report
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting [Yahoo! Finance]
12/7
06:15 pm
sndx
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
Medium
Report
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
12/4
01:52 pm
sndx
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
Low
Report
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
12/3
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/27
07:09 am
sndx
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference [Yahoo! Finance]
11/27
07:00 am
sndx
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Medium
Report
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
11/23
03:33 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/21
10:21 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $33.00 to $38.00. They now have an "overweight" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $33.00 to $38.00. They now have an "overweight" rating on the stock.
11/19
12:22 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at Citigroup Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at Citigroup Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.
11/18
08:09 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $49.00 to $51.00. They now have a "buy" rating on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $49.00 to $51.00. They now have a "buy" rating on the stock.
11/16
12:08 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/15
05:46 pm
sndx
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation [Yahoo! Finance]
Low
Report
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation [Yahoo! Finance]
11/15
05:29 pm
sndx
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Medium
Report
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
11/12
12:36 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.
11/12
07:00 am
sndx
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
High
Report
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
11/8
06:07 am
sndx
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results [Yahoo! Finance]
Low
Report
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results [Yahoo! Finance]
11/7
12:32 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $30.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $30.00 to $33.00. They now have a "buy" rating on the stock.
11/6
08:07 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $45.00 to $47.00. They now have a "buy" rating on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $45.00 to $47.00. They now have a "buy" rating on the stock.
11/5
07:12 pm
sndx
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/5
04:01 pm
sndx
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update